Navigation Links
CytRx Announces Settlement of the Consolidated Securities Class Action Lawsuit

LOS ANGELES, Dec. 10, 2015 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it reached a successful agreement to settle the consolidated securities class action lawsuit pending in the United States District Court for the Central District of California, titled In re CytRx Corporation Securities Litigation.  The consolidated case was brought against the company and/or a number of current and former directors and officers following allegations of stock promotion. The agreement was reached in connection with a voluntary mediation led by the Honorable Judge Dickran Tevrizian, a retired federal judge from the Central District of California.

The settlement agreement contains no admission of liability or wrongdoing and includes a full release of CytRx and the current and former directors and officers in connection with the allegations. CytRx believes the allegations are completely without merit, and is settling the lawsuit to avoid potentially lengthy and costly litigation. The settlement is subject to definitive documentation, shareholder notice, and court approval. 

The terms of the agreement provide for a settlement payment to the class of $4,000,000, of which at least $3,500,000 will be paid by the Company's insurance carriers. The Company will also issue $4,500,000 worth of shares to the class, which will be between a minimum of 1,200,000 shares of common stock and a maximum of 1,800,000 shares of common stock to the class depending on the prevailing stock price at the time of the court's final approval of the settlement agreement. 

"We are pleased to reach a settlement agreement on the securities class action and believe it is in the best interests of CytRx and our shareholders. We will continue to focus on our pre-commercial activities for aldoxorubicin, our pivotal, global Phase 3 trial with aldoxorubicin in second-line soft tissue sarcomas, our newly designated drug candidate DK049, and additional research and development with our LADR technology," said Steven A. Kriegsman, Chairman and CEO.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin, and DK049, a novel drug conjugate which is expected to enter clinic trials in 2016.  CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx's clinical testing of aldoxorubicin and preclinical testing of its LADR™ linker technology platform, the outcome, timing or results of CytRx's clinical testing of aldoxorubicin, the risk that any future pre-clinical or human testing of compounds based on the LADR™ technology platform might not show efficacy or reduced side effects of those compounds, risks related to CytRx's ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx's need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 2 and Phase 3 clinical development of aldoxorubicin for SCLC and STS, respectively, and the preclinical and clinical development of compounds based on the LADR™ technology platform, risks related to lawsuits that have been brought against the Company and its officers and/or directors for alleged violations of the securities laws, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
CytRx Corporation
David J. Haen
Vice President, Business Development and Investor Relations
(310) 826-5648, ext 304

Investor Relations:
Alexander Capital, LP
(855) 288-ALEX (2539)


SOURCE CytRx Corporation
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. CytRx Nominates Next Clinical Drug Candidate DK049
2. CytRx Announces Participation at the 26th Annual Oppenheimer Healthcare Conference
3. CytRx Announces the Completion of Enrollment in Pivotal Global Phase 3 Trial Ahead of Schedule
4. CytRx Reports 2015 Third Quarter Financial Results
5. CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference
6. CytRx Reports 2015 Second Quarter Financial Results
7. CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares
8. CytRx Announces Pricing of Public Offering of 9.1 Million Shares of Common Stock
9. CytRx Announces Proposed Public Offering of Common Stock
10. CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposis Sarcoma
11. Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board of Directors
Post Your Comments:
(Date:2/10/2020)... ... 10, 2020 , ... A device that teaches toddlers to go to sleep ... sleep training system for children, launching today on Kickstarter. Hush Buddy creates and reinforces ... Sleep System, getting a child to sleep soundly is as easy as ready, read, ...
(Date:2/10/2020)... Ky. (PRWEB) , ... February 10, 2020 , ... ... partnership with Healthstat , a leading provider of onsite health clinics. Focused ... SaaS-based population health management software, Healthward ® at its onsite employee health ...
(Date:2/9/2020)... ... , ... Clarence Moses-EL allowed AYBOS to capture his former ... years of wrongful incarceration (Moses-EL was acquitted in 2016). AYBOS Communication Director calls ... in the compounded judicial trauma, destruction of evidence, inhumane treatment and disregard for ...
Breaking Medicine Technology:
(Date:2/11/2020)... ... February 11, 2020 , ... There are many reasons why ... but the service that truly raises us above our competitors is our true Peer ... a board-certified Radiologist with years of clinical experience. We understand that it is impossible ...
(Date:2/11/2020)... (PRWEB) , ... February 11, 2020 , ... The wait is finally over. The first ... Nordisk. For years, this squad has been associating professional sports to a truly special project. ... the world made up entirely of athletes with diabetes. They decided to take on the ...
(Date:2/11/2020)... N.C. (PRWEB) , ... February 11, 2020 , ... ... Meat Handbook Revised and Expanded Second Edition: From Sourcing to Butchery, Mindful Meat ... Meredith Leigh and published by New Society Publishers, this new version brings discussions ...
(Date:2/10/2020)... ... 2020 , ... R3 Medical Training is now enrolling for its PDO ... training consists of thread lift placement on real patients for the face, abdomen and ... an excellent alternative currently for nonoperative facelift. The procedures are safe, quick and with ...
(Date:2/10/2020)... (PRWEB) , ... February 10, 2020 , ... C. A. ... Marketing LLC. At the time he was still in the music business as a ... for AYBOS to create marketing campaigns for HNF, and HNF to create any music ...
Breaking Medicine News(10 mins):